한글목차

펜니들 시장 규모는 2024년 18억 1,000만 달러에서 2030년에는 30억 8,000만 달러에 이를 것으로 예상됩니다. 예측 기간 중 CAGR은 9.2%가 될 것으로 보입니다.

노인은 노화에 의해 인슐린 저항성, 췌장 기능 저하, 고혈압 및 비만과 같은 병존 질환의 영향을 받기 쉽고, 당뇨병 발병의 위험이 높아집니다. 노화에 따라 혈당를 조절하는 인슐린의 작용이 저하되기 때문에 2형 당뇨병을 발병할 가능성이 높아집니다. 또한 노인의 신체 활동 저하와 라이프 스타일 변화도 당뇨병의 동향 상승의 원인이되었습니다. 노화와 관련된 당뇨병의 이환율 증가는 인슐린 투여 장치, 특히 펜니들에 대한 욕구 증가에 대한 간단한 직접적인 의미를 가지고 있습니다. 인슐린 주사는 노인, 특히 1형 또는 진행된 2형 당뇨병 환자의 당뇨병 관리에 필수적인 요소입니다. 사용 편의성, 편리성, 기존 주사기에 비해 통증을 줄여 펜니들은 특히 노인에게 적합합니다. 많은 노인들이 앓고 있는 다른 질병들에는 관절염이 있는데, 이는 주로 주사기 사용을 방해할 수 있기 때문에 펜니들을 사용하는 인슐린 펜에 대한 선호도가 퍼지고 있습니다.

세계 시장에서 펜니들 시장 점유율은 인슐린 투여 및 기타 주사제에 사용되는 펜형 주사기의 대부분과 광범위하게 호환되므로 표준이 지배적입니다. 이 주사 바늘은 다양한 인슐린 펜에 적합하도록 개발되었으며 모든 층의 환자가 사용할 수 있습니다. 그 단순함과 저렴한 가격이 인기를 끌고 있으며, 그 사용의 용이성은 인구가 어느 쪽인가라고하면 비용에 민감한 지역에서 볼 수 있는 것입니다. 표준 펜니들은 1형 및 2형 당뇨병 환자에게도 적합합니다. 그러므로 표준 펜니들은 이러한 모든 증상에서 널리 사용되며, 환자와 그 건강 관리 제공업체는 이를 사용하기 위한 첫 번째 옵션으로 유지하고 있습니다.

세계 펜니들 시장의 온라인 구매 부문은 전자상거래 플랫폼이 제공하는 이점과 편의성으로 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다. 예를 들어, 웹사이트는 경쟁력 있는 가격을 제공하고 때로는 고객에게 펜니들의 구매를 더 저렴하게 할 수 있는 할인, 프로모션 제공, 번들 거래를 제공합니다. 이 외에도 온라인 쇼핑의 매력은 제품 비교, 고객 리뷰 브라우징, 제품 및 크기의 종합적인 범위의 사용이 더 쉽기 때문에 기존 소매점보다 큽니다. 또한 온라인 플랫폼을 이용할 수 있어 원격지에 있는 고객이나 이동에 불편한 고객에게도 집에서 필기구를 받을 수 있어 접근성이 향상됩니다. 전자상거래의 도입은 편의성이 높고 비용 효율적이기 때문에 온라인 구매 분야가 강력하게 성장할 수 있습니다.

본 보고서에서는 세계의 펜니들 시장에 대해 조사했으며, 유형별, 길이별, 용도별, 구매형태별, 설정별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 업계 동향
• 상환 시나리오
• 가격 분석
• 밸류체인 분석
• 생태계 분석
• Porter's Five Forces 분석
• 공급망 분석
• 규제 분석
• 무역 분석
• 특허 분석
• 주요 이해관계자와 구매 기준
• 사례 연구 분석
• 기술 분석
• 2025-2026년의 주된 회의와 이벤트
• 인접 시장 분석
• AI/생성형 AI가 펜니들 시장에 미치는 영향
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 언멧 요구의 분석
• 투자와 자금조달 시나리오

제6장 펜니들 시장, 유형별

• 서론
• 표준 펜니들
• 안전 펜니들

제7장 펜니들 시장, 길이별

• 서론
• 8mm
• 5mm
• 6mm
• 4mm
• 12mm
• 10mm

제8장 펜니들 시장, 용도별

• 서론
• 인슐린 요법
• 글루카곤 유사 펩티드-1 요법
• 성장 호르몬 요법
• 골다공증
• 기타

제9장 펜니들 시장, 구매 형태별

• 서론
• 처방전 구입
• OTC 구매
• 온라인 구매
• 기타

제10장 펜니들 시장, 의료 환경별

• 서론
• 재택치료
• 병원 및 클리닉
• 기타

제11장 펜니들 시장, 지역별

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 일본
  • 중국
  • 호주 및 뉴질랜드
  • 인도
  • 한국
  • 동남아시아
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타
• 중동 및 아프리카
  • 시장 성장을 가속시키는 만성 질환 증가
  • 중동 및 아프리카의 거시경제 전망
• GCC 국가
  • 시장 성장을 가속시키는 가처분 소득 증가
  • GCC 국가의 거시 경제 전망

제12장 경쟁 구도

• 서론
• 주요 진입기업의 전략/강점
• 수익 분석(2019-2023년)
• 시장 점유율 분석(2023년)
• 기업평가 매트릭스 : 주요 진입기업(2023년)
• 기업평가 매트릭스 : 스타트업/중소기업(2023년)
• 기업평가와 재무지표
• 경쟁 시나리오
• 브랜드/제품 비교
• 주요 기업의 연구 개발비

제13장 기업 프로파일

• 주요 진출기업
  • EMBECTA CORP.
  • NOVO NORDISK A/S
  • B. BRAUN SE
  • YPSOMED
  • TERUMO CORPORATION
  • NIPRO
  • OWEN MUMFORD
  • ARKRAY, INC.
  • ULTIMED, INC.
  • HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
  • MONTMED
  • HTL-STREFA
  • ALLISON MEDICAL, INC.
  • GLUCORX LIMITED
  • BERPU MEDICAL TECHNOLOGY CO., LTD.
• 기타 기업
  • VAN HEEK MEDICAL
  • SIMPLE DIAGNOSTICS
  • IYON HEALTH MEDICAL
  • LINKS MEDICAL PRODUCTS INC.
  • MHC MEDICAL PRODUCTS, LLC
  • ADVACARE PHARMA
  • ARTSANA SPA
  • PROMISEMED MEDICAL DEVICES, INC.
  • TRIVIDIA HEALTH, INC.
  • VOGT MEDICAL VERTRIEB GMBH

제14장 부록

영문목차

The pen needles market is projected to reach USD 3.08 Billion by 2030 from USD 1.81 Billion in 2024 at a CAGR of 9.2% during the forecast period. The elderly are susceptible, due to their age, to insulin resistance, a decrease in pancreatic function, and other comorbid conditions, including hypertension and obesity, which raise the risk of developing diabetes. As people age, the body becomes less responsive to insulin's role in regulating blood sugar, hence increasing the chances of developing Type 2 diabetes. In addition, the reduction in physical activity among older adults, coupled with lifestyle changes, contributes to rising trends of the condition. The increasing incidence rate of diabetes with age has simple direct implications concerning the increased desire for insulin administration devices, especially the pen needles. Insulin injections are an essential component of diabetes management among elderly patients, especially patients with Type 1 or advanced Type 2 diabetes. Ease of use, convenience, and reduced pain compared to traditional syringes make the pen needle particularly suitable for older adults. Other conditions most of the elderly suffer from include arthritis, which could primarily hinder them using syringes, hence developing the preference for insulin pens that use pen needles.

"The standard pen needles segment is accounted for the largest share of global pen needles market."

The market share of pen needles in the global market is dominated by the standard ones because of their wide compatibility with most of the pen injectors used for insulin administration and other injectable drugs. These needles are developed to be able to fit in a variety of insulin pens, making them available to patients across all demographics.Their simplicity and affordability make them popular, and their ease of use is something that is found in regions whose populations are rather cost-sensitive. Standard pen needles are also apt for Type 1 and Type 2 diabetes patients. Other patients also require injectable medications for some other conditions; hence, standard pen needles find wide usage in all these conditions, making the patients and their healthcare providers retain them as a first choice for their use.

"Online purchase segment will grow at the highest CAGR during the forecast period of the global pen needles market."

The online purchase segment of the global pen needles market is expected to have the highest growth rate during the forecast period due to the benefits and convenience that e-commerce platforms have provided. For instance, the websites provide competitive prices and, sometimes, offer discounts, promotional offers, and bundle deals that can make the purchase of pen needles cheaper for customers. Apart from this, the appeal of online shopping is greater than traditional retail shops due to more ease in product comparison, reading customer reviews, and availability of a comprehensive range of products and sizes. The availability on online platforms also increases the accessibility for customers located at remote locations or those with some mobility issues since they can receive their pen needles at home. E-commerce adoption, with more convenience and cost-effectiveness, ensures that the segment of online purchases is going to grow strongly.

"North America to witness the substantial growth rate during the forecast period."

The pen needles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2024, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the pen needles market in 2024. This is largely because of the health care systems that are advanced to facilitate better access to diabetes care. The U.S. and Canada have a well-developed medical infrastructure, making it easy for patients to reach pen needles for insulin delivery devices. Furthermore, with millions of people suffering from diabetes in these regions, there is high demand for effective, as well as user-friendly, delivery solutions. Pen needles are popular for their convenience, ease of use, and minimal discomfort. It is the preferred way to manage Type 1 and Type 2 diabetes. With extensive healthcare coverage, a high patient awareness level, and a large diabetic population, North America is the most significant market for pen needles.

A breakdown of the primary participants (supply-side) for the pen needles market referred to for this report is provided below:

• By Company Type: Tier 1-22%, Tier 2-36%, and Tier 3-42%
• By Designation: C-level-23%, Director Level-28%, and Others-49%
• By Region: North America-38%, Europe-29%, Asia Pacific-23%, Latin America- 6%, and Middle East and Africa- 1% and GCC Countries- 3%

Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).

Research Coverage:

The market study covers the pen needles market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, length, application, mode of purchase, setting and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of Market Dynamics: Drivers (rising incidence of chronic diseases, favorable reimbursements in certain countries, and decreasing prices of insulin formulations) restraints (rising pet care costs, poor reimbursement scenario in emerging countries, and needle anxiety) opportunities (growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes), and challenges (implementation of regulations for safety pen needles, reuse of pen needles, and misuse of injection pens)
• Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the pen needles market.
• Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the pen needles market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the pen needles market like Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), and Terumo Corporation (Japan).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.2.2 MARKET SEGMENTATION
  • 1.2.3 YEARS CONSIDERED
  • 1.2.4 CURRENCY CONSIDERED
• 1.3 LIMITATIONS
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 METHODOLOGY-RELATED LIMITATIONS
• 2.6 STUDY ASSUMPTIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PEN NEEDLES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: PEN NEEDLES MARKET, BY LENGTH AND COUNTRY (2024)
• 4.3 GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 REGIONAL MIX

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of chronic diseases
    • 5.2.1.2 Favorable reimbursements in certain countries
    • 5.2.1.3 Growing adoption of self-administration
    • 5.2.1.4 Decreasing prices of insulin formulations
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Alternative methods of drug delivery
    • 5.2.2.2 Poor reimbursement scenario in emerging markets
    • 5.2.2.3 Needle anxiety
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for biosimilar drugs
    • 5.2.3.2 Emerging economies to offer high-growth potential
    • 5.2.3.3 Rising healthcare expenditure on diabetes
    • 5.2.3.4 Implementation of regulations for safety pen needles
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Reuse of pen needles
    • 5.2.4.2 Misuse of injection pens
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING PREFERENCE FOR SAFETY-ENGINEERED PEN NEEDLES
  • 5.3.2 RISING ADOPTION OF SHORTER AND ULTRA-THIN NEEDLES
• 5.4 REIMBURSEMENT SCENARIO
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE SELLING PRICE OF PEN NEEDLES, BY KEY PLAYER, 2024
  • 5.5.2 AVERAGE SELLING PRICE TREND OF STANDARD PEN NEEDLES, BY REGION, 2022-2024
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8.2 BARGAINING POWER OF SUPPLIERS
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 THREAT OF SUBSTITUTES
  • 5.8.5 THREAT OF NEW ENTRANTS
• 5.9 SUPPLY CHAIN ANALYSIS
• 5.10 REGULATORY ANALYSIS
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
    • 5.10.2.1 North America
      • 5.10.2.1.1 US
      • 5.10.2.1.2 Canada
    • 5.10.2.2 Europe
    • 5.10.2.3 Asia Pacific
      • 5.10.2.3.1 Japan
      • 5.10.2.3.2 China
      • 5.10.2.3.3 India
• 5.11 TRADE ANALYSIS
  • 5.11.1 TRADE ANALYSIS OF NEEDLES, CATHETERS, AND CANNULAE USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES (HS CODE 901839)
  • 5.11.2 EXPORT DATA (HS CODE 901839), 2019-2023
  • 5.11.3 IMPORT DATA (HS CODE 901839), 2019-2023
• 5.12 PATENT ANALYSIS
  • 5.12.1 PATENT PUBLICATION TRENDS FOR PEN NEEDLES
  • 5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 CASE STUDY 1: IMPACT OF CCG-WIDE INSULIN PEN NEEDLE
  • 5.14.2 CASE STUDY 2: PEN NEEDLE DESIGN INFLUENCES EASE INSERTION, PAIN, AND SKIN TRAUMA IN SUBJECTS WITH TYPE 2 DIABETES
  • 5.14.3 CASE STUDY 3: DROPSAFE SAFETY PEN NEEDLE HELPS TO PREVENT ACCIDENTAL NEEDLESTICKS AFTER INJECTIONS
• 5.15 TECHNOLOGY ANALYSIS
  • 5.15.1 KEY TECHNOLOGIES
    • 5.15.1.1 Fluid flow enhancement technology
    • 5.15.1.2 Ultra-thin needle technology
  • 5.15.2 COMPLEMENTARY TECHNOLOGIES
    • 5.15.2.1 Microfabricated needles
    • 5.15.2.2 AI in pen injectors
  • 5.15.3 ADJACENT TECHNOLOGIES
    • 5.15.3.1 Autoinjectors
• 5.16 KEY CONFERENCES & EVENTS, 2025-2026
• 5.17 ADJACENT MARKET ANALYSIS
  • 5.17.1 AUTOINJECTORS MARKET
  • 5.17.2 INSULIN DELIVERY DEVICES MARKET
  • 5.17.3 INJECTION PENS MARKET
  • 5.17.4 NEEDLES MARKET
• 5.18 IMPACT OF AI/GEN AI ON PEN NEEDLES MARKET
• 5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
• 5.20 UNMET NEEDS ANALYSIS
• 5.21 INVESTMENT & FUNDING SCENARIO

6 PEN NEEDLES MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 STANDARD PEN NEEDLES
  • 6.2.1 GREATER PREFERENCE AND AFFORDABILITY OF STANDARD PEN NEEDLES TO SUPPORT GROWTH
• 6.3 SAFETY PEN NEEDLES
  • 6.3.1 GROWING CONCERNS OVER NEEDLESTICK INJURIES TO DRIVE ADOPTION OF SAFETY PEN NEEDLES

7 PEN NEEDLES MARKET, BY LENGTH

• 7.1 INTRODUCTION
• 7.2 8MM
  • 7.2.1 WIDE ADOPTION IN NORTH AMERICA TO BOOST MARKET GROWTH
• 7.3 5MM
  • 7.3.1 SHORTER LENGTH AND LOW PAIN TO FUEL UPTAKE
• 7.4 6MM
  • 7.4.1 FAVORABLE REIMBURSEMENTS TO BOOST DEMAND
• 7.5 4MM
  • 7.5.1 WIDE ADOPTION IN PEDIATRIC INSULIN DELIVERY TO DRIVE DEMAND
• 7.6 12MM
  • 7.6.1 HIGH UTILIZATION OF SHORTER NEEDLES TO LIMIT ADOPTION
• 7.7 10MM
  • 7.7.1 PAINFUL PROCEDURES TO RESTRAIN ADOPTION

8 PEN NEEDLES MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 INSULIN THERAPY
  • 8.2.1 RISING INCIDENCE OF DIABETES TO PROPEL MARKET
• 8.3 GLUCAGON-LIKE PEPTIDE-1 THERAPY
  • 8.3.1 GROWING FOCUS OF PHARMA COMPANIES ON GLP-1 DRUG DEVELOPMENT TO DRIVE MARKET
• 8.4 GROWTH HORMONE THERAPY
  • 8.4.1 AVAILABILITY OF LONG-ACTING TREATMENTS TO AFFECT DEMAND FOR NEEDLES
• 8.5 OSTEOPOROSIS
  • 8.5.1 RISING VITAMIN D DEFICIENCY CASES TO PROPEL MARKET
• 8.6 OTHER APPLICATIONS

9 PEN NEEDLES MARKET, BY MODE OF PURCHASE

• 9.1 INTRODUCTION
• 9.2 PRESCRIPTION-BASED PURCHASE
  • 9.2.1 RETAIL PURCHASES TO SUPPORT MARKET GROWTH
• 9.3 OTC PURCHASES
  • 9.3.1 DISCOUNTS OFFERED BY LOCAL PHARMACIES, SUPPLIERS, AND DISTRIBUTORS TO DRIVE MARKET
• 9.4 ONLINE PURCHASE
  • 9.4.1 CONVENIENCE AND TIME-EFFICIENT BENEFITS TO PROPEL MARKET
• 9.5 OTHER MODES OF PURCHASE

10 PEN NEEDLES MARKET, BY CARE SETTING

• 10.1 INTRODUCTION
• 10.2 HOME CARE SETTINGS
  • 10.2.1 GROWING PREFERENCE FOR SELF-ADMINISTRATION OF INSULIN TO PROPEL MARKET
• 10.3 HOSPITALS & CLINICS
  • 10.3.1 INCREASING ADOPTION OF SAFETY PEN NEEDLES TO DRIVE MARKET
• 10.4 OTHER CARE SETTINGS

11 PEN NEEDLES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing burden of diabetes to contribute to growth
  • 11.2.3 CANADA
    • 11.2.3.1 Growing initiatives for diabetic coverage to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Advanced healthcare system to intensify growth
  • 11.3.3 UK
    • 11.3.3.1 High incidence of cardiovascular disease to favor growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing delivery of insulin devices to propel market
  • 11.3.5 ITALY
    • 11.3.5.1 Low product pricing to support growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Supportive regulations mandating the use of safety pen needles to propel market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Growing inclination toward public health insurance to boost market
  • 11.4.3 CHINA
    • 11.4.3.1 Rising focus on modernizing healthcare to expedite growth
  • 11.4.4 AUSTRALIA & NEW ZEALAND
    • 11.4.4.1 Increasing rate of chronic diseases to amplify growth
  • 11.4.5 INDIA
    • 11.4.5.1 Growing per capita income to fuel market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Increasing geriatric population to facilitate growth
  • 11.4.7 SOUTHEAST ASIA
    • 11.4.7.1 Booming medical tourism industry to drive market
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growing incidence of non-communicable diseases to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Universal health coverage to stimulate growth
  • 11.5.4 ARGENTINA
    • 11.5.4.1 Increasing obesity rates to bolster growth
  • 11.5.5 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 HIGHER DISPOSABLE INCOME TO ENCOURAGE GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PEN NEEDLES MARKET
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Type footprint
    • 12.5.5.4 Length footprint
    • 12.5.5.5 Application footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
• 12.8 COMPETITIVE SCENARIO
  • 12.8.1 PRODUCT LAUNCHES & APPROVALS
  • 12.8.2 DEALS
  • 12.8.3 EXPANSIONS
• 12.9 BRAND/PRODUCT COMPARISON
• 12.10 R&D EXPENDITURE OF KEY PLAYERS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 EMBECTA CORP.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Expansions
      • 13.1.1.3.3 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 NOVO NORDISK A/S
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 B. BRAUN SE
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 MnM view
      • 13.1.3.3.1 Right to win
      • 13.1.3.3.2 Strategic choices
      • 13.1.3.3.3 Weaknesses & competitive threats
  • 13.1.4 YPSOMED
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 TERUMO CORPORATION
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Right to win
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 NIPRO
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Expansions
  • 13.1.7 OWEN MUMFORD
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 ARKRAY, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Expansions
  • 13.1.9 ULTIMED, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
  • 13.1.10 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 MONTMED
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 HTL-STREFA
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 ALLISON MEDICAL, INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 GLUCORX LIMITED
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 BERPU MEDICAL TECHNOLOGY CO., LTD.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 VAN HEEK MEDICAL
  • 13.2.2 SIMPLE DIAGNOSTICS
  • 13.2.3 IYON HEALTH MEDICAL
  • 13.2.4 LINKS MEDICAL PRODUCTS INC.
  • 13.2.5 MHC MEDICAL PRODUCTS, LLC
  • 13.2.6 ADVACARE PHARMA
  • 13.2.7 ARTSANA S.P.A.
  • 13.2.8 PROMISEMED MEDICAL DEVICES, INC.
  • 13.2.9 TRIVIDIA HEALTH, INC.
  • 13.2.10 VOGT MEDICAL VERTRIEB GMBH

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS